Cargando…
Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitors (TKIs) have achieved remarkable clinical progress in the treatment of non-small-cell lung cancer; however, resistance has limited their therapeutic efficacy. Therefore, understanding the mechanisms of VEGF-TKI and ICI...
Autores principales: | Xu, Yingzhuo, Wang, Jian, Wang, Xu, Zhou, Xiaoshu, Tang, Jing, Jie, Xiaohua, Yang, Xijie, Rao, Xinrui, Xu, Yunhong, Xing, Biyuan, Li, Zhenyu, Wu, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786837/ https://www.ncbi.nlm.nih.gov/pubmed/35075132 http://dx.doi.org/10.1038/s41420-022-00818-8 |
Ejemplares similares
-
REV1 promotes lung tumorigenesis by activating the Rad18/SERTAD2 axis
por: Chen, Yunshang, et al.
Publicado: (2022) -
PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
por: Li, Jun, et al.
Publicado: (2022) -
NLRP6 is required for cancer-derived exosome-modified macrophage M2 polarization and promotes metastasis in small cell lung cancer
por: Rao, Xinrui, et al.
Publicado: (2022) -
Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer
por: Zhou, Xiaoshu, et al.
Publicado: (2022) -
Nuclear localization of the tyrosine kinase BMX mediates VEGFR2 expression
por: Liu, Tingting, et al.
Publicado: (2019)